SCHEMBL20158868

SCHEMBL20158868

CCN1CCC(C)(NC(=O)c2cccc(F)c2F)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.42
RET P07949 3/20 0.41
DPP4 P27487 1/20 0.40
HPGD P15428 1/20 0.40
DRD2 P14416 2/20 0.39
USP30 Q70CQ3 1/20 0.38
KAT6A Q92794 1/20 0.38
CES2 O00748 1/20 0.38
BCHE P06276 1/20 0.38
CES1 P23141 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD11B1 P28845 1/20 0.37
P2RX7 Q99572 1/20 0.37
OPRM1 P35372 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
GAA P10253 1/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068944 0.81 HPGD (0.44) CCR3RETDPP4HPGDDRD2
SCHEMBL20147547 0.81 RET (0.43) CCR3RETDPP4HPGDDRD2
SCHEMBL20152065 0.81 HPGD (0.40) CCR3RETDPP4HPGDUSP30
SCHEMBL22857091 0.81 CHRM5 (0.48) CCR3RETHPGDP2RX7
SCHEMBL21652054 0.79 RET (0.43) RETDPP4USP30
SCHEMBL20206040 0.79 DPP4 (0.43) CCR3RETDPP4NPC1RAB9A
SCHEMBL22857090 0.79 NPC1 (0.48) CCR3RETNPC1RAB9ASMN1; SMN2
SCHEMBL20147565 0.78 HPGD (0.42) CCR3RETDPP4HPGDKAT6A
SCHEMBL25503681 0.75 RET (0.42) CCR3RETDPP4DRD2OPRM1
SCHEMBL21652022 0.73 CCR3 (0.50) CCR3RETDPP4DRD2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CCR3 1128/4885RET 1/4885DPP4 1963/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CCR3 1128/4885RET 1/4885DPP4 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.